Dengue Virus

15 registered clinical trials studyying Dengue Virus — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-b NCT06859619	University Hospital, Montpellier	N/A
Completed	Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003) NCT05507450	Merck Sharp & Dohme LLC	Phase 2
Unknown	Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuat NCT03141138	U.S. Army Medical Research and Development Command	Phase 1
Completed	Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD) NCT02794181	National Institutes of Health Clinical Center (CC)	—
Completed	A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet C NCT02305732	Cerus Corporation	—
Completed	Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine NCT01084291	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Safety and Immune Response to an Investigational Dengue Type 2 Vaccine NCT01073306	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin NCT00993447	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore NCT00880893	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects NCT00875524	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Efficacy and Safety of Dengue Vaccine in Healthy Children NCT00842530	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years NCT00788151	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults NCT00740155	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in th NCT00617344	Sanofi	Phase 2
Completed	Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects NCT00730288	Sanofi	Phase 2